Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs

Autor: Mirjan Thys, Leon Meyer, William R. Everett, Sean P. Mahabir, Kristina Kryda, Susan J. Holzmer, Csilla Becskei, David R. Young, Sara Chapin, Lori Carter
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Flea
Veterinary medicine
Time Factors
animal diseases
Ctenocephalides canis
Administration
Oral
medicine.disease_cause
Parasite Load
chemistry.chemical_compound
0302 clinical medicine
Pyrantel
Dog Diseases
Acaricides
biology
Reproduction
Ctenocephalides felis
Moxidectin
Drug Combinations
Treatment Outcome
Infectious Diseases
Canis
Flea infestation
Female
Macrolides
Speed of kill
medicine.drug
Oral combination
030231 tropical medicine
Placebo
lcsh:Infectious and parasitic diseases
Single oral dose
03 medical and health sciences
Dogs
Flea Infestations
Infestation
parasitic diseases
medicine
Animals
Spiro Compounds
lcsh:RC109-216
Research
biology.organism_classification
bacterial infections and mycoses
030104 developmental biology
chemistry
Azetidines
Parasitology
Ctenocephalides
Zdroj: Parasites & Vectors, Vol 13, Iss 1, Pp 1-8 (2020)
Parasites & Vectors
ISSN: 1756-3305
DOI: 10.1186/s13071-020-3944-3
Popis: Background Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs. Methods Based on pre-treatment flea counts, dogs were randomly allocated to treatment with a single, oral dose of either placebo or Simparica Trio™ at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) on Day 0. All dogs were infested with approximately 100 unfed, adult fleas (C. felis or C. canis) prior to treatment and weekly for 5 weeks post-treatment. In Studies 1, 2 and 3, the number of viable fleas were comb-counted at 24 h after treatment and after each weekly infestation; Study 2 also included groups treated with tablets containing sarolaner-alone (1.2 mg/kg), moxidectin-alone (24 µg/kg) or pyrantel-alone (5 mg/kg). In Study 4, flea counts were conducted at 3, 4, 8 and 12 h after treatment and subsequent weekly infestations to establish speed of kill. In Study 5 (flea reproduction), dogs were housed in an enclosure designed to facilitate collection of flea eggs. Results Efficacy of Simparica Trio™ against C. felis was ≥ 99.7% and against C. canis was 100% at 24 h after treatment and after subsequent infestations for at least 35 days. Treatment with sarolaner-alone had similar efficacy to Simparica Trio™, while moxidectin-alone and pyrantel-alone were no different from placebo at most time points. In Study 4, significant flea killing started at 4 h after treatment; by 8 h after treatment, all treated dogs were free of fleas. Following weekly re-infestation, the combination product reduced fleas by ≥ 97.8% within 12 h for 28 days. Simparica Trio™ reduced flea egg-laying by 100% for 35 days. No treatment-related adverse reactions occurred in any study. Conclusions A single dose of Simparica Trio™ at the recommended minimum dose provided highly efficacious and rapid treatment within 4 h of existing flea infestations and persistent control of fleas on dogs for 5 weeks. The efficacy against fleas resulted in 100% prevention of flea reproduction for over a month following a single oral dose.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje